Skip to main content
Year archive

BioInvent International — 2016 filings

All 60 regulatory filings released by BioInvent International (BINV) in 2016, sourced directly from the official regulator.

60 Filings
2016 Period
2016 filings (60)
Filing Released Lang
Major Shareholding Notification 2016
Major Shareholding Notification
2016-12-30 English
Kallelse till extra bolagsstämma i BioInvent International AB
AGM Information
2016-12-30 Swedish
Notice of Extraordinary General Meeting in BioInvent International AB
AGM Information
2016-12-30 English
BioInvent announces Cancer Immunotherapy Research Collaboration and License Agreement with Pfizer and issues new shares to Pfizer
Capital/Financing Update
2016-12-21 English
BioInvent ingår forskningssamarbete och licensavtal inom cancerimmunterapi med Pfizer och gör en nyemission till Pfizer
Capital/Financing Update
2016-12-21 Swedish
BioInvent avslutar pågående fas II-studie med BI-505
Regulatory Filings
2016-12-09 Swedish
BioInvent terminates current BI-505 Phase II study
Legal Proceedings Report
2016-12-09 English
BioInvent rapporterar ”clinical hold” för fas II-studie med BI-505
Legal Proceedings Report
2016-11-08 Swedish
BioInvent reports clinical hold on BI-505 phase II study
Legal Proceedings Report
2016-11-08 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-11-07 English
Interim / Quarterly Report 2016
Interim / Quarterly Report 9M 2016
2016-10-25 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report 9M 2016
2016-10-25 English
BioInvent erhåller förstärkt patentskydd för BI-505 – en immunonkologisk läkemedelskandidat i fas II-prövning mot myelom
Regulatory Filings
2016-09-19 Swedish
BioInvent expands patent approvals for its lead clinical immuno-oncology programme in multiple myeloma, BI-505
Regulatory Filings
2016-09-19 English
BioInvent extends manufacturing services contract with major global pharmaceutical client; expects to generate approximately SEK 8 million in revenue
Regulatory Filings
2016-08-29 English
BioInvent utökar avtal om produktionstjänster för större globalt läkemedelsbolag – intäkterna väntas uppgå till cirka 8 miljoner kronor
Regulatory Filings
2016-08-29 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report H2 2016
2016-07-26 Swedish
Earnings Release 2016
Earnings Release H2 2016
2016-07-26 English
BioInvent ingår utvecklings- och produktionssamarbete med Alligator
Regulatory Filings
2016-07-08 Swedish
BioInvent enter process development and manufacturing collaboration with Alligator
Regulatory Filings
2016-07-08 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-24 English
Resolution at BioInvent’s Annual General Meeting 2016
AGM Information
2016-05-12 English
Beslut på BioInvents årsstämma 2016
AGM Information
2016-05-12 Swedish
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-12 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-09 English
BioInvent’s Board Director Dharminder Chahal increases his shareholding in the company
Director's Dealing
2016-05-06 English
BioInvents styrelseledamot Dharminder Chahal ökar sitt aktieinnehav i bolaget
Major Shareholding Notification
2016-05-06 Swedish
Major Shareholding Notification 2016
Major Shareholding Notification
2016-05-02 English
BioInvent, Oncurious NV och NMTRC startar fas I/IIa-studie med TB-403 för behandling av medulloblastom
Regulatory Filings
2016-05-02 Swedish
BioInvent, Oncurious NV and NMTRC initiating Phase I/IIa study with TB-403 for the treatment of Medulloblastoma
Regulatory Filings
2016-05-02 English
Ändring av antalet aktier och röster i BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2016-04-29 Swedish
Change in the number of shares and votes in BioInvent International AB
Declaration of Voting Results & Voting Rights Announcements
2016-04-29 English
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-04-26 Swedish
Interim / Quarterly Report 2016
Interim / Quarterly Report Q1 2016
2016-04-26 English
Multiple myeloma phase II study of BioInvent's antibody BI-505 ready to start
Regulatory Filings
2016-04-18 English
Klinisk fas II-studie med BioInvents antikropp BI-505 mot multipelt myelom redo för start
Investor Presentation
2016-04-18 Swedish
BioInvents företrädesemission slutförd
Capital/Financing Update
2016-04-15 Swedish
BioInvent’s rights issue completed
Share Issue/Capital Change
2016-04-15 English
Kallelse till årsstämma i BioInvent International AB
AGM Information
2016-04-11 Swedish
Annual General Meeting in BioInvent International AB
AGM Information
2016-04-11 English
BioInvent publishes prospectus
Capital/Financing Update
2016-03-23 English
BioInvent offentliggör prospekt
Capital/Financing Update
2016-03-23 Swedish
Annual Report 2015
Annual Report FY 2015
2016-03-23 Swedish
Annual Report 2015
Annual Report FY 2015
2016-03-23 English
Beslut vid extra bolagsstämma i BioInvent
AGM Information
2016-03-18 Swedish
Resolutions of the Extraordinary General Meeting of BioInvent
AGM Information
2016-03-18 English
BioInvent is granted a patent in Europe for the immune-oncology antibody BI-505
Regulatory Filings
2016-03-16 English
BioInvent beviljas patent i Europa för den immunonkologiska antikroppen BI-505
Regulatory Filings
2016-03-16 Swedish
BioInvent and Oncurious partner with US research consortium to accelerate phase I/IIa trial of TB-403
Regulatory Filings
2016-03-15 English
BioInvent och Oncurious samarbetar med amerikanskt forskningsnätverk för att påskynda fas I/IIa-prövning av TB-403
Regulatory Filings
2016-03-15 Swedish
BioInvent receives €2 million milestone payment from Daiichi Sankyo for licensed n-CoDeR® antibody progressing into Phase I clinical trial
Regulatory Filings
2016-02-29 English
BioInvent erhåller milstolpsbetalning på 2 miljoner euro från Daiichi Sankyo för licensierad n-CoDeR®-antikropp i samband med start av en fas I-studie
Capital/Financing Update
2016-02-29 Swedish
Earnings Release 2015
Earnings Release Q4 2015
2016-02-17 Swedish
Audit Report / Information 2015
Audit Report / Information FY 2015
2016-02-17 English
Kallelse till extra bolagsstämma i BioInvent International AB
AGM Information
2016-02-17 Swedish
Notice of Extraordinary General Meeting in BioInvent International AB
AGM Information
2016-02-17 English
BioInvent issues private placement to US-based healthcare investor Omega Funds in parallel to offering a fully guaranteed rights issue
Share Issue/Capital Change
2016-02-16 English
BioInvent genomför riktad emission till den USA-baserade health care-investeraren Omega Funds samt en fullt ut garanterad företrädesemission
Share Issue/Capital Change
2016-02-16 Swedish
BioInvent meddelar att FDA har godkänt IND-ansökan för fas I/IIa-studien med TB-403
Regulatory Filings
2016-01-07 Swedish
BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403
Regulatory Filings
2016-01-07 English